Introduction {#s1}
============

*Acinetobacter baumannii* is increasingly involved in nosocomial infections, especially in the ICU setting. This pathogen is frequently MDR and has shown a propensity to adapt to the environment through up-regulation of intrinsic resistance and acquisition of antibiotic resistance determinants.^[@DKV378C1],[@DKV378C2]^ Another parameter that modulates the progression of resistance is an increase in general mutation rate (hypermutability), which can influence resistance development through mutation,^[@DKV378C3]^ frequency of lateral gene transfer,^[@DKV378C4]^ up-regulated gene expression and compensatory evolution of a bacterial population.^[@DKV378C5]^

Studies of mutator distribution and level of hypermutability have shown that ≤50% of clinical isolates from a variety of bacterial species exhibit a mutator phenotype/genotype. Many of these mutators are found among infection-causing bacteria, which are isolated from an environment of high selective pressure due to intense antibiotic usage.^[@DKV378C6]^ No previous study has evaluated the existence of mutator isolates in an *A. baumannii* population, to our knowledge. The aims of this study were to determine the prevalence of mutators in *A. baumannii* and their hypermutability and to explore whether there is any correlation between changes in the mutation frequency (*f*) and antibiotic resistance.

Materials and methods {#s2}
=====================

Bacterial isolates, antimicrobials and culture media {#s2a}
----------------------------------------------------

Two-hundred-and-thirty-seven *A. baumannii* isolates originating from Europe, the USA and Sweden between 1990 and 2007 were investigated.^[@DKV378C7],[@DKV378C8]^ *A. baumannii* ATCC 19606 was chosen as a comparator strain for *f* assays due to its isolation in 1948 and exposure to less antibiotic selection pressure. The WT *Escherichia coli* MG1655, *E. coli dam* (*damΔ* 16::Kan^r^) and *mutS* (*ΔmutS*::FRT) mutants were used as quality-control strains.^[@DKV378C9]^ All experiments were performed in freshly prepared Mueller--Hinton (MH) broth and MH agar (BD, Sweden); rifampicin was purchased from Sigma-Aldrich, Sweden.

Susceptibility testing {#s2b}
----------------------

Resistance profiles were determined using Etest (Biodisk/bioMérieux, Sweden) and/or disc diffusion (BD/Fisher Scientific, Sweden). The EUCAST clinical breakpoints were used for sorting isolates into antibiotic resistance profile groups (ARPGs) as follows; susceptible, susceptible to all antibiotic groups tested; resistant, resistant to one or two antibiotic groups; and MDR, resistant to three to five antibiotic groups.^[@DKV378C10]^ ARPGs are defined in Table [1](#DKV378TB1){ref-type="table"}. Table 1.Allocation of 237 isolates into ARPGs and the median and geometric mean *f* of isolates in ARPGsARPG (*n*)Percentage of totalPercentage of isolates in each group with a specific resistance phenotype (*n*)Median *f*Geometric mean *f* (SD)Median fold increase in *f* compared with that of ATCC 19606Geometric mean fold increase in *f* compared with that of ATCC 19606 (SD)Percentage of mutators in ARPGTETCEPCARAMGFQSusceptible (75)32000006.4E−099.6E−09 (1.2E−08)0.921.37 (1.67)10.7Resistant (43)1816 (7)54 (23)042 (18)56 (24)6.2E−097.6E−09 (6.7E−09)0.901.09 (0.96)6.98MDR (119)5055 (65)92 (109)35 (42)88 (105)70 (83)8.4E−092.3E−08 (1.1E−07)1.203.23 (15.3)21.8Total (237)10030 (72)56 (132)18 (42)52 (123)45 (107)7.0E−091.6E−08 (7.6E−08)1.002.25 (10.8)15.6[^1]

Determination of *f* against rifampicin {#s2c}
---------------------------------------

To determine *f*, assays were performed as previously described by Baquero *et al*.^[@DKV378C11]^ Ten independent cultures for each isolate were grown overnight with shaking, and cells were plated onto MH plates with and without rifampicin (100 mg/L).

The distribution of *f* values in the population was categorized as previously described (Table [1](#DKV378TB1){ref-type="table"}).^[@DKV378C11],[@DKV378C12]^ The *f* values were normalized to control strain ATCC 19606 (*f* = 7 × 10^−9^), which was set at 1. Isolates with an ≥2.5- to 10-fold higher *f* were defined as weak mutators and those with a \>10-fold higher *f* were defined as strong mutators.

Data comparison and statistical methods {#s2d}
---------------------------------------

Isolates were grouped according to their ARPGs and further into hypo-normomutators (*f* \< 2.5-fold) and mutators (*f* ≥ 2.5-fold) before analysis. The Mann--Whitney *U*-test and Kruskal--Wallis analysis of variance (ANOVA) statistical methods were used to compare resistance groups. For associations between ARPG and the number of mutator isolates in each group, the Pearson\'s χ^2^ test was used, and logistic regression was used to further investigate the relationship between these variables. *P* values \<0.05 were considered significant.

Results {#s3}
=======

Antimicrobial susceptibility profiles {#s3a}
-------------------------------------

The division of isolates and the percentage of each isolate in each ARPG are shown in Table [1](#DKV378TB1){ref-type="table"}.

Distribution of f values in bacterial populations {#s3b}
-------------------------------------------------

The frequency of rifampicin resistance was determined, and isolates were sorted according to their *f*, which varied between 2.2 × 10^−10^ and 1.2 × 10^−6^ (Figure [1](#DKV378F1){ref-type="fig"}). A sharp peak in frequency distribution was found at ∼10^−8^; however, 68% of the population had a lower frequency. To the right of the peak, 15% of the isolates had a moderately higher *f*, whereas only two isolates (\<0.1%) had a frequency \>10^−7^ (Figure [1](#DKV378F1){ref-type="fig"}a). No *A. baumannii* isolate displayed hypermutability as high as that of the *E. coli mutS* strain (*f* = 3 × 10^−6^), and only one isolate (*f* = 1.1 × 10^−6^) had a frequency higher than that of the *E. coli dam*-knockout strain (*f* = 3.9 × 10^−7^). When the population was sorted according to their ARPGs, the distribution of the susceptible group showed three peaks, at 2 × 10^−9^, 6 × 10^−9^ and 1 × 10^−8^, respectively, while the frequencies of the resistant group were spread over the whole interval, and for the MDR group, ∼45% of the isolates were clustered in a sharp peak, with *f* ranging between 8 × 10^−9^ and 2 × 10^−8^ (Figure [1](#DKV378F1){ref-type="fig"}b). Figure 1.Distribution of *f* of 237 *A. baumannii* isolates. (a) Vertical continuous lines indicate the division of isolates into categories by their mutability status: H, hypomutators (*f* ≤4 × 10^−9^); N, normomutators (4 × 10^−9^ \< *f* \< 1.7 × 10^−8^); W, weak mutators (1.7 × 10^−8^ \< *f* \< 7 × 10^−8^); and S, strong mutators (*f* \>7 × 10^−8^).^[@DKV378C11],[@DKV378C12]^ The vertical broken line indicates *f* for the control strain *A. baumannii* ATCC 19606 (7 × 10^−9^). (b) Distribution of *f* when isolates are divided according to their ARPGs. Numbers in brackets indicate numbers of isolates in respective ARPGs. SUS, susceptible; RES, resistant.

Hypermutability and resistance profile in mutator isolates {#s3c}
----------------------------------------------------------

Compared with the *A. baumannii* ATCC 19606 control strain, 200 isolates had an *f* ranging between 0.03-fold and \<2.5-fold. Of these, 80 were classified as hypomutators (\<1.0-fold), composed of 39% susceptible, 19% resistant and 43% MDR isolates, respectively. The overall occurrence of weak and strong mutators was ∼16%; when the population was divided into ARPGs, the prevalence of mutators in the MDR group (22%) was significantly higher (*P* \< 0.05) than the prevalence in the susceptible and resistant groups (11% and 7%, respectively). The geometric mean and median of *f* for the population and the percentage of mutators in each ARPG are presented in Table [1](#DKV378TB1){ref-type="table"}.

Thirty-seven isolates had an ≥2.5- to 166-fold increase in *f* (73% with ≥2.5- to 5-fold, 19% with \>5- to 10-fold and 8% with \>10-fold) ([Table S1, available as Supplementary data at *JAC* Online](http://jac.oxfordjournals.org/lookup/suppl/doi:10.1093/jac/dkv378/-/DC1)). Of the mutators, 70% were MDR isolates with a median/mean increase *f* of 3.6/11.1-fold (Figure [2](#DKV378F2){ref-type="fig"}a). There was no significant difference in increased *f* between the mutators in the susceptible, resistant and MDR groups (*P* = 0.51--0.74) (Figure [2](#DKV378F2){ref-type="fig"}a). However, there was a significant correlation between MDR and increased *f* (*P* \< 0.05) (Figure [2](#DKV378F2){ref-type="fig"}b). Figure 2.(a) Differences in geometric mean and median fold increase in *f* in the ARPGs. Each ARPG is subdivided into normal (*f* \< 2.5-fold, hypo- and normomutators) and mutator (*f* ≥ 2.5-fold, weak and strong mutators) groups. (b) Distribution of isolates with increased *f* and increased multidrug resistance. The results of the Wilcoxon Mann--Whitney *U*-test showed that there was a significantly higher mean *f* among isolates with an MDR profile (*P* \> 0.05). SUS, susceptible; RES, resistant.

Of the 34 weak mutators, 7, 3 and 24 of the isolates had a susceptible, resistant and MDR phenotype, respectively. All the weak resistant mutators (*f* 3.19--4.29-fold) were susceptible to cephalosporins and carbapenems, with a varied range of susceptibility to the other ARPGs. Four weak MDR mutators (*f* 2.51--3.25-fold), which displayed antibiotic resistance to three of five antibiotic groups, were all susceptible to the carbapenem group in combination with susceptibility to either the tetracycline-like, aminoglycoside or fluoroquinolone group of antibiotics. Of the remaining 20 weak MDR isolates, nine were resistant to all antibiotic groups (*f* 3.14--8.29-fold), 5 were resistant to all except tetracycline-like antibiotics (*f* 2.57--5.89-fold) and 6 were resistant to all except carbapenem-group antibiotics (*f* 2.71--10.0-fold) ([Table S1](http://jac.oxfordjournals.org/lookup/suppl/doi:10.1093/jac/dkv378/-/DC1)).

The remaining three strong mutators, one susceptible isolate and two MDR isolates, displayed 11.1-fold (AB95), 19.5-fold (AB279) and 166-fold (AB190) increased *f* ([Table S1](http://jac.oxfordjournals.org/lookup/suppl/doi:10.1093/jac/dkv378/-/DC1)). In comparison with the control mutator *E. coli* strains (*dam* and *mutS* mutants, 55.7- and 429-fold increased *f*), the AB190 isolate can be regarded as a strong mutator.

Discussion {#s4}
==========

This study is the first one, to our knowledge, on the occurrence of mutators in an *A. baumannii* population, and we have shown that 16% of isolates from our collection displayed an ≥2.5- to 166-fold increase in *f*. The prevalence of mutators and their *f* values were significantly higher in the MDR group compared with those of the susceptible and resistant groups. We also found 0.42% and 15.2% of isolates to be strong and weak mutators, respectively, which are around the same range as findings for *E. coli* urinary tract isolates, where the proportions were ∼0.5%--1% and 25%--40% for strong and weak mutators, respectively.^[@DKV378C11],[@DKV378C13]^

Variation in mutation rates and its effect on resistance development and bacterial adaptability have been studied extensively over recent years. It was shown that even a small (2--4-fold) increase in mutation rate can drive the evolution of fluoroquinolone resistance, and, furthermore, a slight increase in *f* favours the evolution of MDR.^[@DKV378C9],[@DKV378C14]^ In *E. coli,* selection with rifampicin and ciprofloxacin showed that mutator strains generated both higher resistance levels and resistance mutations with ≤1000-fold higher *f*.^[@DKV378C15]^

Studies of clinical isolates have revealed that weak mutators can be present at earlier stages of infection, and a modestly elevated mutation rate can give them an adaptive advantage.^[@DKV378C16]^

Another aspect of mutators is the notion that some genotypes can exhibit increased frequency of recombination, interspecies recombination and transformation.^[@DKV378C17],[@DKV378C18]^ These events might explain in part the ability of *A. baumannii* to adapt, whereby a mutator can integrate DNA that carries resistance markers and/or increase the chance of gaining mutations that promote the survival of the organism in clinical settings.

Carbapenems are still the drugs of choice to treat *A. baumannii* infections, even though resistance rates are increasing.^[@DKV378C1]^ To understand the progression of carbapenem resistance, Zander *et al*.^[@DKV378C19]^ investigated three isolates recovered from patients during an outbreak in a hospital in Krakow, Poland. Sequencing of *bla*~OXA\ 51-like~ genes showed that carbapenem resistance was caused by a conversion of OXA-66 into OXA-82 and that *bla*~OXA-82~ was also associated with the IS element IS*Aba1*. A second study looked at related isolates possessing similar plasmids that encode the carbapenemase OXA-58 and exhibit varying levels of carbapenem resistance. Sequencing revealed genetic variability composed of multiple copies of the *bla*~OXA\ 58~ gene and that extra copies were due to IS-element transposition or recombination events.^[@DKV378C20]^ These adaptive modifications could be elevated in a population composed of mutators, where hypermutability can drive the progression of survival and evolution of genetic elements such as β-lactamase genes. However, whether any of the genetic changes seen in these studies was due to an altered mutation rate is not known.

In conclusion, we have shown that 16% of the *A. baumannii* strains were weak-to-strong mutators and that there was a strong correlation with an increased *f* with an MDR phenotype. The fact that a high percentage of MDR *A. baumannii* isolates show an increased mutability in clinical settings calls for further studies that could form the basis of novel treatment strategies.
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[^1]: TET, tetracycline-like group (tetracycline, tigecycline, doxycycline); CEP, cephalosporin group (cefepime, ceftazidime); CAR, carbapenem group (meropenem, imipenem); AMG, aminoglycoside group (gentamicin, tobramycin, amikacin); and FQ, fluoroquinolone group (ciprofloxacin, levofloxacin); SD, standard deviation.
